Back to GetFilings.com



Table of Contents

 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

 
FORM 10-Q
 
x
 
QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
  
 
For the quarterly period ended September 30, 2002
 
or
 
¨
 
TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE EXCHANGE ACT
 
  
 
For the transition period from                          to                         
 
Commission File Number 1-15445
 

 
DRUGMAX, INC.,
(Formerly DrugMax.com, Inc.)
(Exact name of registrant as specified in its charter)
 
Nevada
 
34-1755390
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
 
12505 Starkey Road, Suite A, Largo, Florida 33773
(Address of principal executive offices)
 
(727) 533-0431
(Registrant’s telephone number, including area code)
 

 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  x  Yes  ¨  No
 
As of November 16, 2002, there were 7,119,172 shares of common stock, par value $0.001 per share, outstanding.
 


Table of Contents
 
DRUGMAX, INC. AND SUBSIDIARIES
FORM 10-Q
FOR THE QUARTER ENDED SEPTEMBER 30, 2002
 
TABLE OF CONTENTS
 
    
Page #

PART I    FINANCIAL INFORMATION
    
Item 1.
  
Financial Statements
    
       
3
       
4
       
5
       
6
Item 2.
     
12
       
15
Item 3.
     
16
Item 4.
     
16
PART II    OTHER INFORMATION
    
Item 1.
     
16
Item 4.
     
17
Item 6.
     
17
  
20
  
21
  
22

2


Table of Contents
 
PART I—FINANCIAL INFORMATION
 
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
 
DRUGMAX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
 
    
September 30,
2002

    
March 31,
2002

 
           
(As Restated-See Note I)
 
ASSETS
                 
Current assets:
                 
Cash and cash equivalents
  
$
154,042
 
  
$
167,373
 
Restricted cash
  
 
2,000,000
 
  
 
2,000,000
 
Accounts receivable, net of allowance for doubtful accounts of $1,237,575 and $340,575
  
 
16,146,988
 
  
 
14,001,696
 
Inventory
  
 
17,945,333
 
  
 
20,682,439
 
Due from affiliates
  
 
22,871
 
  
 
23,498
 
Net deferred income tax asset—current
  
 
748,000
 
  
 
465,630
 
Prepaid expenses and other current assets
  
 
1,352,749
 
  
 
624,207
 
    


  


Total current assets
  
 
38,369,983
 
  
 
37,964,843
 
Property and equipment, net
  
 
900,647
 
  
 
989,921
 
Goodwill
  
 
13,105,000
 
  
 
25,314,298
 
Intangible assets, net
  
 
—  
 
  
 
276,914
 
Shareholder notes receivable
  
 
100,000
 
  
 
100,000
 
Notes receivable
  
 
662,441
 
  
 
607,417
 
Net deferred income tax asset—long term
  
 
749,336
 
  
 
637,918
 
Deferred financing costs, net
  
 
182,101
 
  
 
215,477
 
Other assets
  
 
151,091
 
  
 
151,226
 
Deposits
  
 
42,307
 
  
 
44,743
 
    


  


Total assets
  
$
54,262,906
 
  
$
66,302,757
 
    


  


LIABILITIES AND STOCKHOLDERS’ EQUITY
                 
Current liabilities:
                 
Accounts payable
  
$
15,477,516
 
  
$
13,844,766
 
Accrued expenses and other current liabilities
  
 
368,342
 
  
 
421,318
 
Credit lines payable
  
 
18,486,770
 
  
 
18,929,575
 
Current portion of long-term debt and capital leases
  
 
684,965
 
  
 
676,365
 
Due to affiliates
  
 
4,377
 
  
 
4,377
 
    


  


Total current liabilities
  
 
35,021,970
 
  
 
33,876,401
 
Long-term debt and capital leases
  
 
139,297
 
  
 
478,200
 
Other long-term liabilities
  
 
525,263
 
  
 
501,561
 
    


  


Total liabilities
  
 
35,686,530
 
  
 
34,856,162
 
    


  


Commitments and contingencies (Note F)
                 
Stockholders’ equity:
                 
Preferred stock, $.001 par value; 2,000,000 shares authorized; no preferred shares issued or outstanding
  
 
—  
 
  
 
—  
 
Common stock, $.001 par value; 24,000,000 shares authorized; 7,119,172 shares issued and outstanding
  
 
7,120
 
  
 
7,120
 
Additional paid-in capital
  
 
40,967,355
 
  
 
40,967,355
 
Accumulated deficit
  
 
(22,398,099
)
  
 
(9,527,880
)
    


  


Total stockholders’ equity
  
 
18,576,376
 
  
 
31,446,595
 
    


  


Total liabilities and stockholders’ equity
  
$
54,262,906
 
  
$
66,302,757
 
    


  


 
See accompanying notes to condensed consolidated financial statements.

3


Table of Contents
 
DRUGMAX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
 
    
For the Three Months Ended September 30, 2002

    
For the Three Months Ended September 30, 2001

    
For the Six Months Ended September 30, 2002

    
For the Six Months Ended September 30, 2001

 
Revenues
  
$
73,736,121
 
  
$
66,187,701
 
  
$
136,839,940
 
  
$
137,064,013
 
Cost of goods sold
  
 
71,456,335
 
  
 
64,510,873
 
  
 
132,579,328
 
  
 
133,585,897
 
    


  


  


  


Gross profit
  
 
2,279,786
 
  
 
1,676,828
 
  
 
4,260,612
 
  
 
3,478,116
 
    


  


  


  


Selling, general and administrative expenses
  
 
1,817,584
 
  
 
1,217,208
 
  
 
4,375,865
 
  
 
2,312,787
 
Amortization expense
  
 
49,483
 
  
 
28,352
 
  
 
91,376
 
  
 
56,705
 
Depreciation expense
  
 
73,615
 
  
 
50,235
 
  
 
147,529
 
  
 
100,054
 
Goodwill impairment
  
 
12,209,298
 
  
 
—  
 
  
 
12,209,298
 
  
 
—  
 
Intangible asset impairment
  
 
258,914
 
  
 
—  
 
  
 
258,914
 
  
 
—  
 
    


  


  


  


Total operating expenses
  
 
14,408,894
 
  
 
1,295,795
 
  
 
17,082,982
 
  
 
2,469,546
 
    


  


  


  


Operating (loss) income
  
 
(12,129,108
)
  
 
381,033
 
  
 
(12,822,370
)
  
 
1,008,570
 
    


  


  


  


Other income (expense):
                                   
Interest income
  
 
21,831
 
  
 
18,383
 
  
 
48,082
 
  
 
41,672
 
Other income (expense)
  
 
16,335
 
  
 
(4,769
)
  
 
25,692
 
  
 
(4,769
)
Interest expense
  
 
(258,748
)
  
 
(275,431
)
  
 
(515,411
)
  
 
(536,639
)
    


  


  


  


Total other expense
  
 
(220,582
)
  
 
(261,817
)
  
 
(441,637
)
  
 
(499,736
)
    


  


  


  


(Loss) income before income tax benefit
  
 
(12,349,690
)
  
 
119,216
 
  
 
(13,264,007
)
  
 
508,834
 
Income tax benefit
  
 
51,159
 
  
 
616,250
 
  
 
393,788
 
  
 
1,110,280
 
    


  


  


  


Net (loss) income
  
$
(12,298,531
)
  
$
735,466
 
  
$
(12,870,219
)
  
$
1,619,114
 
    


  


  


  


Net (loss) income per common share—basic
  
$
(1.73
)
  
$
0.11
 
  
$
(1.81
)
  
$
0.23
 
    


  


  


  


Net (loss) income per common share—diluted
  
$
(1.73
)
  
$
0.10
 
  
$
(1.81
)
  
$
0.23
 
    


  


  


  


Weighted average shares outstanding—basic
  
 
7,119,172
 
  
 
6,968,754
 
  
 
7,119,172
 
  
 
6,968,754
 
    


  


  


  


Weighted average shares outstanding—diluted
  
 
7,119,172
 
  
 
7,152,225
 
  
 
7,119,172
 
  
 
7,150,143
 
    


  


  


  


 
See accompanying notes to condensed consolidated financial statements.

4


Table of Contents
 
DRUGMAX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
 
    
For the Six Months Ended September 30, 2002

    
For the Six Months Ended September 30, 2001

 
Cash flows from operating activities:
                 
Net (loss) income
  
$
(12,870,219
)
  
$
1,619,114
 
Adjustments to reconc